Everolimus in Refractory Testicular Germ Cell Cancer

Status Completed

Clinical Trial Summary

Everolimus in refractory testicular germ cell cancer. Everolimus 10 mg /day/ is administered to the patient until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements. Feasibility of surgical resection will be assessed after every 2 cycles of the treatment in patients with partial response.

Clinical Trial Description

Treatment Schedule: Everolimus will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.

Estimated duration of treatment: Until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.

Feasibility of surgical resection will be assessed after every 2 cycles of the treatment in patients with partial response. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01466231
Study type	Interventional
Source	National Cancer Institute, Slovakia
Contact
Status	Completed
Phase	Phase 2
Start date	November 2011
Completion date	June 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06133543` - Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer	N/A
Terminated	`NCT00369291` - CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant	Phase 1
Terminated	`NCT00198172` - Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors	Phase 2
Recruiting	`NCT05874063` - Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors	Phase 3
Completed	`NCT03194906` - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors	Phase 2
Recruiting	`NCT04791228` - A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors	Phase 2
Active, not recruiting	`NCT03418844` - Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy	N/A
Recruiting	`NCT05889585` - Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated With High-dose Chemotherapy and Autologous Stem Cell Transplant
Recruiting	`NCT05394675` - A Study of DS-9606a in Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT03067181` - Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors	Phase 3
Withdrawn	`NCT03960151` - Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy	Phase 2
Active, not recruiting	`NCT03158064` - Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors	Phase 2
Completed	`NCT03950830` - Disulfiram and Cisplatin in Refractory TGCTs.	Phase 2
Recruiting	`NCT00898755` - Collecting and Storing Tissue From Young Patients With Cancer
Recruiting	`NCT04804007` - Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT	Phase 2
Terminated	`NCT02988843` - Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors	Phase 2
Recruiting	`NCT05259605` - Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Active, not recruiting	`NCT03638167` - EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors	Phase 1
Recruiting	`NCT04308330` - Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies	Phase 1
Recruiting	`NCT06418789` - High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors	Phase 2